Epilepsy – Access & Reimbursement – Detailed, Expanded Analysis (US)

Despite the large number of currently marketed antiepileptic drugs (AEDs), important unmet needs remain for new therapies to treat refractory epilepsy and seizure syndromes such as Lennox-Gastaut syndrome, Dravet syndrome, and acute repetitive seizures. Several novel therapies have reached or will soon reach the U.S. market that will help address the needs of patients within these niche segments; however, this wave of premium-priced brands—some with orphan-level pricing—will enter a cost-sensitive market dominated by generics. Anticipating payers’ receptivity to emerging products and how future coverage policies could affect patient access and neurologists’ treatment choice are crucial for drug developers entering an increasingly crowded market for a clinically complex disease.


  • What is the current state of coverage for key AED brands in the U.S. market? What restrictions do payers impose, and how do market access dynamics influence surveyed neurologists’ prescribing?
  • How receptive are payers to late-phase emerging therapies? What coverage decisions do they anticipate? How do neurologists expect to prescribe the agents?
  • What actions can developers take to optimize market access?

Markets covered: United States

Key companies: Aquestive Therapeutics, GW Pharmaceuticals, Neurelis, SK Biopharmaceuticals, UCB, Zogenix, Biocodex, Sunovion, Eisai

Key drugs covered: Generic SOCs, Vimpat, Fycompa, Aptiom, Briviact, Epidiolex, Xcopri, Nayzilam, Valtoco, Fintepla, padsevonil, Libervant, Diacomit


U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.

launch Related Market Assessment Reports